about
Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D 2 (300,000 IU).Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone.How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits.From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis.Relationship between insulin sensitivity and bone mineral density in primary hyperparathyroidism.Higher circulating parathormone is associated with smaller and weaker bones in obese children.Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study.Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
P2860
Q34761795-CB4458B1-DD85-4E1D-B218-55D152149D39Q35885233-20771D9E-EAFA-4D37-9CFD-8A4E41677ED1Q36031246-2135844A-0A6C-4B32-B330-B64FA6B16BCBQ36880655-79322EE6-D6BC-430D-971D-779FE739ABFAQ38367220-E8DD3EED-D4D7-449A-B4C6-7DC2A8D9E522Q38411782-FE8158A7-CDCA-4BBC-B5CF-49C60160B452Q39024329-4F09BD0C-844C-4011-9FD8-D18D5E41FB77Q39680232-C5E01E6F-C623-43A7-AE88-9A69C37F2D16Q44066537-D3FAE4FB-A1CA-44AE-A5FA-65DFB2BC0A65Q45340912-1AD19C32-B90E-4ACC-8679-8E007FE6987FQ47621636-969694CC-7232-4852-85DD-BC4DE140D450Q47723896-4F6ABBA5-7392-4285-A22F-6DDE69176084Q47970372-A42FDA73-BDC0-44EE-BAF8-F179F2FBA8E4Q51216875-411B39F7-0F49-4AEB-937C-35801C50FE3AQ51307682-1284D60F-42FC-4D13-A72F-263FD861DB37Q53469719-C98D7E75-0355-40E9-9264-25F0EC02CEEC
P2860
description
im Februar 2013 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 22 February 2013
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2013
@uk
name
Sclerostin and DKK1 in Primary Hyperparathyroidism
@en
Sclerostin and DKK1 in Primary Hyperparathyroidism
@nl
type
label
Sclerostin and DKK1 in Primary Hyperparathyroidism
@en
Sclerostin and DKK1 in Primary Hyperparathyroidism
@nl
prefLabel
Sclerostin and DKK1 in Primary Hyperparathyroidism
@en
Sclerostin and DKK1 in Primary Hyperparathyroidism
@nl
P2093
P2860
P50
P1476
Sclerostin and DKK1 in primary hyperparathyroidism
@en
P2093
Elena Fracassi
Ombretta Viapiana
Silvano Adami
Sonila Troplini
P2860
P2888
P304
P356
10.1007/S00223-012-9665-7
P407
P577
2013-02-22T00:00:00Z